Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis

Multiple Sclerosis and Related Disorders- United States

doi 10.1016/j.msard.2016.10.010

Full Text

Abstract

Available in

Date

November 1, 2016

Authors

Mark S. Freedman

Xavier Montalban

Aaron E. Miller

Catherine Dive-Pouletty

Steven Hass

Karthinathan Thangavelu

Thomas P. Leist

Publisher

Elsevier BV

Related search

Assessing the Comparative Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of “Number Needed to Treat” Analysis

English

Nd3 - Meta-Analysis of Real-World Adherence and Persistence of Maintenance Once- Or Twice-Daily Oral Disease-Modifying Drugs (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Multiple Sclerosis

English

Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy

English

Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain

English

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical

2019

English

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

English

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Neuropsychiatric Disease and Treatment

Psychiatry

Mental Health

Biological Psychiatry

2010

English

Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies

Iraqi Journal of Pharmaceutical Sciences

English

Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials

JAMA - Journal of the American Medical Association

Medicine

2002

English

Amanote Research

Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis

Multiple Sclerosis and Related Disorders- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Assessing the Comparative Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of “Number Needed to Treat” Analysis

Nd3 - Meta-Analysis of Real-World Adherence and Persistence of Maintenance Once- Or Twice-Daily Oral Disease-Modifying Drugs (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Multiple Sclerosis

Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy

Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis

Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies

Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials

Amanote Research

Comparing Outcomes From Clinical Studies of Oral Disease-Modifying Therapies (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Relapsing MS: Assessing Absolute Differences Using a Number Needed to Treat Analysis

Multiple Sclerosis and Related Disorders- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Assessing the Comparative Outcomes From Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of “Number Needed to Treat” Analysis

Nd3 - Meta-Analysis of Real-World Adherence and Persistence of Maintenance Once- Or Twice-Daily Oral Disease-Modifying Drugs (Dimethyl Fumarate, Fingolimod, and Teriflunomide) in Multiple Sclerosis

Pnd55 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Italy

Pnd56 - A Cost-Effectiveness Analysis Using Real-World Data From the Msbase Registry: Comparing Natalizumab to Fingolimod in Patients With Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in Spain

HDL-cholesterol Elevation Associated With Fingolimod and Dimethyl Fumarate Therapies in Multiple Sclerosis

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

Disease-Modifying Therapies in Relapsing&ndash;remitting Multiple Sclerosis

Comparing the Quality of Life Among Patients With Relapsing Remitting Multiple Sclerosis in Iraq Using Different Disease Modifying Therapies

Reporting Number Needed to Treat and Absolute Risk Reduction in Randomized Controlled Trials

Disease-Modifying Therapies in Relapsing–remitting Multiple Sclerosis